Record seizure of smart drugs including one untested in humans shows growing market

November 3, 2014 by Barbara Sahakian, The Conversation
On the up. Angry Parsley, CC BY-SA

People desire to enhance themselves in all sorts of ways: physically through cosmetic surgery; sexually through Viagra; and through using cognitive enhancing, or smart, drugs to perform better at school or work. In such a globally competitive environment it is likely that the market for the last of these will continue to grow.

The use of these drugs by healthy people for lifestyle reasons is increasing. This has been documented, both by formal and informal surveys and by the Care Quality Commission's data on prescriptions for (Ritalin); 56% in the past five years in England alone. The increase in has been attributed to several factors, including the potential for diversion and misuse, and the CQC has recommended that methylphenidate use be monitored carefully.

In a survey published in Nature, 62% of (1,400) users of smart drugs reported taking methylphenidate, making it the most popular choice. Another 44% reported taking modafinil and 15% said they had taken beta blockers such as propranolol. The survey also reported that a third of the drugs that were used for non-medical purposes were purchased over the internet.

A new class

In my publications on this topic and my lectures, I have warned about the harms of purchasing these prescription-only drugs over the internet. There seems now to be another class of drugs which is being purchased over the internet: the racetams, which are used for the treatment of dementia or cognitive impairment.

Many clinical trials and reviews, including a Cochrane review, have looked at the use of piracetam, one of the original racetams, but there now seem to be more potent ones.

In general, these drugs are said to enhance brain metabolism and neuro-protection. Nefiracetam binds to a receptor in the brain called GABA-A and allows activity at even more receptors, including ones called NMDA, which play a part in controlling synaptic plasticity and memory function. Nefiracetam has been shown to effectively treat apathy and motivation issues in patients after stroke. Another, aniracetam has been shown to modulate the AMPA receptor and has actions on others called D2, nACh and 5-HT2A in the brain. Noopept is derived from the racetam family of drugs and shares similar mechanisms of actions, but is far more potent than piracetam, which is used to treat epilepsy.

For treatments currently approved by the regulatory bodies there is advice and information for all these drugs that tell you how fast different ones work, what they do and the benefits of choosing one over another.

The market

The Medicines and Healthcare products Regulatory Agency (MHRA) recently announced the UK's biggest-ever single seizure of smart drugs. With more than 20,000 units, of 13 different types of cognitive enhancement medicines, the seizure had a value of about £200,000. The drugs seized from a UK website included noopept, phenylpiracetam, centrophenoxine, oxiracetam, sunifiram, citicoline and aniracetam, which illustrates the burgeoning demand and variety of the new active substances entering the marketplace.

The seizure came following intelligence from the Norwegian Medicines Agency, after a number of packages were detained by Norwegian customs, and a full investigation was initiated by the MHRA.

So the demand is there. But what are the concerns about the use of these drugs? For one, there are no long-term safety and efficacy studies of these drugs in healthy people. One of the drugs seized, Sunifiram, has never been subject to involving humans.

Furthermore, we know that the brain is in development into late adolescence. Therefore we do not know the long-term consequences of the effects of these drugs on a healthy developing brain. It may give a boost now, but what will be the effect of repeated use down the line? We just don't know. Without consultation from a doctor, counter-indications that suggest you shouldn't use them, such as other medications which may interact with these drugs or a pre-existing medical condition, may not be clear.

Many young people also purchase these drugs via the internet, which is a very dangerous way of obtaining prescription-only drugs, because you do not know what you actually purchasing. As Alistair Jeffrey, the MHRA's head of enforcement, put it: "If you are acquiring medicines over the internet without a prescription then you are purchasing from an unknown, unregulated and ultimately an unlawful source that has one objective – to take your money."

Legitimate uses

There are important benefits to society of cognitive enhancing drugs, particularly when considering people with neuro-psychiatric disorders, such as Alzheimer's disease, and brain injury.

However, use by healthy people is an issue. Both the International Neuroethics Society and the Society for Neuroscience have discussed the ethical issues of this increasing use of these drugs by healthy people. And the impact of this on neuroscience and on society requires urgent further discussion among professionals and the public.

While reports have acknowledged that there may be a role for these in sections of society, including in the military and for doctors working through the night, there is an urgent need for long-term studies of their safety and efficacy in healthy people. There is a role for government and pharmaceuticals companies to prevent harms in healthy users by conducting these trials.

If we can stop the ravages of Alzheimer's disease on the minds of elderly people and improve the educational experience and outcome for disadvantaged young people with attention deficit hyperactivity disorder (ADHD), then it is clearly worth further developing these drugs – they may prove essential to improving functionality, quality of life and well-being. But for , exercise, education or lifelong learning are excellent ways to boost your brain power.

Explore further: Smart drugs pose special risks to the developing brain of young people

Related Stories

Smart drugs pose special risks to the developing brain of young people

May 13, 2014
Over a million American students misuse prescription drugs or take illegal stimulants to increase their attention span, memory, and capacity to stay awake. Such "smart drugs" become more and more popular due to peer pressure, ...

Experimental brain tumour therapy considered for NHS fast track

September 18, 2014
A new immunotherapy for a form of brain cancer has become the first in the UK to be designated (link is external) a 'Promising Innovative Medicine' (PIM) as part of a scheme to speed up access to experimental new treatments.

Physicians should not prescribe ADD drugs to healthy people

December 17, 2012
Physicians in Canada should consider refusing to prescribe cognitive enhancement medications—also used to treat attention deficit disorder (ADD)—to healthy patients, states an analysis article in CMAJ (Canadian Medical ...

Researchers explore new possibilities for the treatment of epilepsy

October 1, 2014
Ongoing research at Iowa State University is investigating the connection between initial seizures and the onset of epilepsy later in life.

Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment

July 9, 2014
Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy ...

Police seize millions in huge fake Viagra swoop

September 1, 2014
Police in several European countries on Monday arrested 12 people and seized millions of euros in assets in a swoop on counterfeit Viagra dealers, authorities said.

Recommended for you

Health insurance plans may be fueling opioid epidemic

June 22, 2018
Health care insurers including Medicare, Medicaid and major private insurers have not done enough to combat the opioid epidemic, suggests a study led by researchers at Johns Hopkins Bloomberg School of Public Health.

Overdose risk quintuples with opioid and benzodiazepine use

June 22, 2018
In the first 90 days of concurrent opioid and benzodiazepine use, the risk of opioid-related overdose increases five-fold compared to opioid-only use among Medicare recipients, according to a new study from the University ...

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.